-
2
-
-
0036200879
-
Survival among U.S. women with invasive epithelial ovarian cancer
-
McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399-403.
-
(2002)
Gynecol Oncol
, vol.84
, pp. 399-403
-
-
McGuire, V.1
Jesser, C.A.2
Whittemore, A.S.3
-
3
-
-
0036498788
-
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
-
Bristow RE, Tomacruz RS, Armstrong DK, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1248-1259
-
-
Bristow, R.E.1
Tomacruz, R.S.2
Armstrong, D.K.3
Montz, F.J.4
-
4
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
-
(1996)
N Engl J Med
, vol.334
, pp. 1-6
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.F.3
-
5
-
-
0000121237
-
Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
-
Ozols RF, Bundy BN, Fowler J et al. Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [Abstract 1373]. Proc ASCO 1999;18:356a.
-
(1999)
Proc ASCO
, vol.18
-
-
Ozols, R.F.1
Bundy, B.N.2
Fowler, J.3
-
6
-
-
0002324260
-
Survival and longer-term toxicity results of the SCOTROC study: Docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC)
-
Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [Abstract 804]. Proc ASCO 2002;21:202a.
-
(2002)
Proc ASCO
, vol.21
-
-
Vasey, P.A.1
-
7
-
-
0030698757
-
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
-
Efsenhauer EA, Vermorken JM, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
-
(1997)
Ann Oncol
, vol.8
, pp. 963-968
-
-
Efsenhauer, E.A.1
Vermorken, J.M.2
Van Glabbeke, M.3
-
8
-
-
0034049605
-
Second-line treatment of ovarian cancer
-
Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
-
(2000)
Oncologist
, vol.5
, pp. 26-35
-
-
Markman, M.1
Bookman, M.A.2
-
9
-
-
0027066977
-
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
-
Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992;47:282-6.
-
(1992)
Gynecol Oncol
, vol.47
, pp. 282-286
-
-
Vergote, I.1
Himmelmann, A.2
Frankendal, B.3
Scheistroen, M.4
Vlachos, K.5
Trope, C.6
-
10
-
-
0031028270
-
Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125
-
Rustin GJ, Nelstrop AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-6.
-
(1997)
J Clin Oncol
, vol.15
, pp. 172-176
-
-
Rustin, G.J.1
Nelstrop, A.E.2
Crawford, M.3
-
11
-
-
0031193915
-
Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature
-
Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997;66:20-6.
-
(1997)
Gynecol Oncol
, vol.66
, pp. 20-26
-
-
Manetta, A.1
Tewari, K.2
Podczaski, E.S.3
-
12
-
-
0032103330
-
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecologic Oncology Group phase II trial
-
Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998;69:226-9.
-
(1998)
Gynecol Oncol
, vol.69
, pp. 226-229
-
-
Markman, M.1
Blessing, J.A.2
Moore, D.3
Ball, H.4
Lentz, S.S.5
-
13
-
-
0035072411
-
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer
-
Malik IA. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol 2001;31:69-73.
-
(2001)
Jpn J Clin Oncol
, vol.31
, pp. 69-73
-
-
Malik, I.A.1
-
14
-
-
0034897130
-
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III ovarian cancer: A Southwest Oncology Group trial (SWOG-9326)
-
Rothenberg ML, Liu PY, Wilcznski S et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82:317-22.
-
(2001)
Gynecol Oncol
, vol.82
, pp. 317-322
-
-
Rothenberg, M.L.1
Liu, P.Y.2
Wilcznski, S.3
-
15
-
-
0026634982
-
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer
-
Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-11.
-
(1992)
J Clin Oncol
, vol.10
, pp. 706-711
-
-
Alberts, D.S.1
Green, S.2
Hannigan, E.V.3
-
16
-
-
0346423733
-
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
-
Alberts DS, Lui PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 1996;335:1950-5.
-
(1996)
New Engl J Med
, vol.335
, pp. 1950-1955
-
-
Alberts, D.S.1
Lui, P.Y.2
Hannigan, E.V.3
-
17
-
-
0035865144
-
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
-
Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1001-1007
-
-
Markman, M.1
Bundy, B.N.2
Alberts, D.S.3
-
18
-
-
0034886499
-
Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-1 inhibitors and perspective of the Gynecologic Oncology Group
-
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-1 inhibitors and perspective of the Gynecologic Oncology Group. Int J Gynecol Cancer, 2001;11 (Suppl. 1):42-51.
-
(2001)
Int J Gynecol Cancer
, vol.11
, Issue.SUPPL. 1
, pp. 42-51
-
-
Bookman, M.A.1
-
19
-
-
0038690538
-
Phase III randomized trial of 12 versus 3 months if maintenance paclitaxel in patients with advanced ovarian cancer after complete recovery to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
-
Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months if maintenance paclitaxel in patients with advanced ovarian cancer after complete recovery to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-73.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2460-2473
-
-
Markman, M.1
Liu, P.Y.2
Wilczynski, S.3
-
20
-
-
0034600305
-
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
-
Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst, 2000;92:699-708.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 699-708
-
-
Piccart, M.J.1
Bertelsen, K.2
James, K.3
|